Bioequivalence and Bioavailability Forum 04:21 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

ElMaestro
Hero

Denmark,
2018-04-15 14:50

Posting: # 18684
Views: 707

Shenanigans [BE/BA News]

Hi all,

story from New York Times.

I have seen some cases of the same phenomenon in Europe, when wholesalers have been very forthcoming with supplies of trial material until they are told it is for use as a comparator in a BE trial. Then suddenly there is 'a problem with the supply chain' or some such vague excuse for quickly terminating the call.

—

 if (3) 4 



x=c("Foo", "Bar") 

b=data.frame(x) 

typeof(b[,1]) ##aha, integer?

b[,1]+1 ##then let me add 1

Best regards,
ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.

Bioequivalence and Bioavailability Forum | Admin contact
19,154 posts in 4,080 threads, 1,308 registered users;
online 15 (0 registered, 15 guests [including 5 identified bots]).

One can show the following: given any rule, however “fundamental”
or “necessary” for science, there are always circumstances
when it is advisable not only to ignore the rule,
but to adopt its opposite. Paul Feyerabend

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by

Ing. Helmut Schütz